Neurophysiology of Parkinson's disease: From basic research to clinical correlates

Clinical Neurophysiology

Volumn 110, Issue 12, 1999, Pages 2006-2013

  Centonze, Diego ^a   Calabresi, Paolo ^a,b   Giacomini, Patrizia ^c   Bernardi, Giorgio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine; Nigrostriatal neurones; Parkinson's disease

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

BRAIN ELECTROPHYSIOLOGY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; NERVE DEGENERATION; NEUROPHYSIOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0032702254     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-2457(99)00173-X     Document Type: Article

References (82)

1. Anglade P., Mouatt-Prigent A., Agid Y., Hirsch E.C. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 5:1996;121-128.
2. Arbuthnot T.G.W. Supersensitivity of dopamine receptors. Bradford H.F., Marsden C.D. Biochemistry and neurology. 1976;27-34 Academic Press, London.
3. Ariano M.A., Larson E.R., Noblett K.L., Sibley D.R., Levine M.S. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse. 26:1997;400-414.
4. Artola A., Singer W. Long-term potentiation and NMDA receptors in rat visual cortex. Nature. 330:1987;649-652.
5. Bergman H., Feingold A., Nini A., Raz A., Slovin H., Abeles M., Vaadia E. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. 21:1998;32-38.
6. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: toward a dynamic approach. Prog Neurobiol. 55:1998;93-116.
7. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev. 21:1997;447-453.
8. Bouyer J.J., Park D.H., Joh T.H., Pickel V.M. Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res. 302:1984;267-275.
9. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA. 92:1995;7105-7109.
10. Calabresi P., Benedetti M., Mercuri N.B., Bernardi G. Depletion of catecholamines reveals inhibitory effects of bromocryptine and lysuride on neostriatal neurones recorded intracellularly in vitro. Neuroscience. 20:1988;757-771.
11. Calabresi P., De Murtas M., Mercuri N.B., Bernardi G. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. Ann Neurol. 31:1992;366-373.
12. Calabresi P., Maj R., Pisani A., Mercuri N.B., Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci. 12:1992;4224-4233.
13. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent blockade of NMDA receptor channel. Eur J Neurosci. 4:1992;929-935.
14. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons: implications for Parkinson's disease. Brain. 116:1993;433-452.
15. Calabresi P., Pisani A., Centonze D., Bernardi G. Role of Ca2+ in striatal LTD and LTP. Semin Neurosci. 8:1996;321-328.
16. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. The corticostriatal projection: from synaptic plasticity to basal ganglia disorders. Trends Neurosci. 19:1996;19-24.
17. Calabresi P., Saiardi A., Pisani A., Baik J-H., Centonze D., Mercuri N.B., Bernardi G., Borrelli E. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci. 17:1997;4536-4544.
18. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol. 43:1998;586-597.
19. Calabresi P., Centonze D., Gubellini P., Bernardi G. Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology. 38:1999;323-326.
20. Calabresi P., Gubellini P., Centonze D., Sancesario G., Morello M., Giorgi M., Pisani A., Bernardi G. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci. 19:1999;2489-2499.
21. Carroll C.B., Holloway V., Brotchie J.M., Mitchell I.J. Neurochemical and behavioural investigations of the NMDA receptor associated glycine site in the rat striatum: functional implications for treatments of parkinsonian symptoms. Psychopharmacology. 119:1995;55-65.
22. Centonze D., Gubellini P., Picconi B., Giacomini P., Calabresi P., Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol. 1999;. in press.
23. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 1998;. 51 (Suppl 2): S30-S35.
24. Choi S., Lovinger D.M. Decreased probability of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses. Proc Natl Acad Sci USA. 94:1997;2665-2670.
25. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev. 21:1997;455-468.
26. Desmond N.L., Levy W.B. Morphological correlates of long-term potentiation imply the modification of existing synapses, not synaptogenesis, in the hippocampal dentate gyrus. Synapse. 5:1990;139-143.
27. Freund T.F., Powell J.F., Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience. 13:1984;1189-1215.
28. Fuxe K., Ungerstedt U. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-striatal DA pathway and quantitative recording of rotational behaviour. Pharmacol Ther. 2:1976;41-47.
29. Gossel M., Schmidt W.J., Loscher W., Zajaczkowski W., Danysz W. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J Neural Transm. 10:1995;27-39.
30. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;l33-154.
31. Graybiel A.M., Aosaki T., Flaherty A., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1994;1826-1831.
32. Greenamyre J.T., O'Brien C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol. 48:1991;977-981.
33. Groves P.M. A theory of functional organization of the neostriatum and neostriatal control of voluntary movement. Brain Res Rev. 5:1983;109-132.
34. Hagan J.J., Middlemiss D.N., Sharpe P.C., Poste G.H. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol Sci. 18:1997;156-163.
35. Hornykiewicz O. Parkinson's disease and the adaptative capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Narabayashi H., Nagatsu T., Yanagisawa N., Mizuno Y. Advances in neurology Vol. 60. 1993;140-147 Raven Press, New York.
36. Ingham C.A., Hood S.H., Arbuthnott G.W. Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age. Brain Res. 503:1989;334-338.
37. Ingham C.A., Hood S.H., van Maldegem B., Weeninck A., Arbuthnott G.W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res. 93:1993;17-27.
38. Ito M. Long-term depression. Ann Rev Neurosci. 12:1989;85-102.
39. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci. 13:1993;4908-4923.
40. Kawaguchi Y., Wilson C.J., Augood S.J., Emerson P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
41. Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurons are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci Lett. 66:1986;106-112.
42. Kish S.J., Rajput A., Gilbert J., et al. Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol. 20:1986;26-31.
43. Koetter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol. 44:1994;163-196.
44. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 21:1997;447-453.
45. Lapper S.R., Bolam J.P. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience. 51:1992;533-545.
46. Lindefors N., Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett. 115:1990;248-252.
47. Lindefors N., Brene S., Herrera-Marschitz M., Persson H. Region specific regulation of glutamic acid decarboxylase mRNA expression by dopamine neurons in rat brain. Exp Brain Res. 77:1989;611-620.
48. Lovinger D.M., Tyler E.C., Merrit A. Short- and long-term synaptic depression in the neostriatum. J Neurophysiol. 70:1993;1937-1949.
49. Lozano A.M., Lang A.E., Hutchison W.D., Dostrovsky J.O. New developments in understanding the etiology of Parkinson's disease and its treatment. Curr Opin Neurobiol. 8:1998;783-790.
50. Marin C., Papa S.M., Engberg T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
51. McNeill T.H., Brown S.A., Rafols J.A., Shoulson I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 445:1988;148-152.
52. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 88:1999;1-16.
53. Morello M., Reiner A., Sancesario G., Karle E.J., Bernardi G. Ultrastructural study of nitric oxide synthase-containing striatal neurons and their relationship with parvalbumin-containing neurons in rats. Brain Res. 776:1997;30-39.
54. Nitsch C., Riesenberg R. Synaptic reorganisation in the rat striatum after dopaminergic deafferentation: an ultrastructural study using glutamate decarboxylase immunocytochemistry. Synapse. 19:1995;247-263.
55. Papa S.M., Chase T.N. Levodopa-induced dyskiynesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol. 39:1996;574-578.
56. Pennartz C.M.A., Ameerun R.F., Groenewegen H.J., Lopes da Silva F.H. Synaptic plasticity in an in vitro slice preparation of the rat nucleus accumbens. Eur J Neurosci. 5:1993;107-117.
57. Saavedra J.M., Setler P.E., Kebebian J.W. Biochemical changes accompanying unilateral 6-hydroxydopamine lesions in rat substantia nigra. Brain Res. 151:1978;339-352.
58. Salin P., Kerkerian L., Heidet V., Epelbaum J., Nieoullon A. Somatostatin-immunoreactive neurons in the rat striatum: effects of corticostriatal and nigrostriatal dopaminergic lesions. Brain Res. 521:1990;23-32.
59. Schultz W. Depletion of dopamine in the striatum as an experimental model of parkinsonism: direct effects and adaptive mechanisms. Prog Neurobiol. 18:1982;121-166.
60. Schultz W., Ungerstedt U. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp Brain Res. 33:1978;159-171.
61. Schwarting R.K.W., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 50:1996;275-331.
62. Seasack S.R., Aoki C., Pickel V.M. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci. 14:1994;88-106.
63. Siggins G.R., Hoffer B.J., Bloom F.E., Ungerstedt U. Cytochemical and electrophysiological studies of dopamine in the caudate nucleus. Research Publications: Association for Research in Nervous and Mental Disease. 55:1976;227-248.
64. Sivam S.P., Breese G.R., Krause J.E., Napier T.C., Muller R.A., Hong J-S. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachynin and enkephalin gene expression. J Neurochem. 49:1987;1623-1633.
65. Smith A.D., Bolam J.P. The neuronal network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265.
66. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
67. Stern E.A., Jaeger D., Wilson C.J. Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo. Nature. 394:1998;475-478.
68. Teyler T.J., DiScenna P. Long-term potentiation as a candidate mnemonic device. Brain Res Rev. 7:1984;15-28.
69. Thal C.J., Sharpless N.S., Hirschhorn I.D., Horowitz S.G., Makman M.H. Striatal met-enkephalin concentration increases following nigrostriatal denervation. Biochem Pharmacol. 32:1983;3297-3301.
70. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand. 367:1971;49-68.
71. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand. 367:1971;69-93.
72. Ungerstedt U., Ljungberg T., Hoffer B., Siggins G. Dopaminergic supersensitivity in the striatum. Adv Neurol. 9:1975;57-65.
73. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
74. Vernier P., Julen J-F., Rataboul P., Fourrier O., Feuerstein C., Mallet J. Similar time course changes in striatal levels of glutamic acid decarboxylase and proenkephalin mRNA following dopaminergic deafferentation in the rat. J Neurochem. 51:1988;1375-1380.
75. Vincent S.T., Nagy J.I., Fibiger H.C. Increased striatal glutamate decarboxylase after lesions of the nigrostriatal pathway. Brain Res. 143:1978;168-173.
76. Von Voigtlander P.F., Moore K.E. Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine. L-DOPA, amantadine, amphetamine and other psycomotor stimulants. Neuropharmacology. 12:1973;451-462.
77. Voorn P., Jorritsma-Byham B., van Dijk C., Buijs R.M. The dopaminergic innervation of the ventral striatum in the rat: a light- and electron-microscopical study with antibodies against dopamine. J Comp Neurol. 251:1986;84-99.
78. Walsh J.P. Depression of excitatory input in rat striatal neurons. Brain Res. 608:1993;123-128.
79. Weiss L.T., Chesselet M-F. Regional distribution and regulation of preprosomatostatin messenger RNA in the striatum as revealed by in situ hybridization histochemistry. Mol Brain Res. 5:1989;121-130.
80. Wilson C.J., Groves P.M. Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular injection of horseradish peroxidase. J Comp Neurol. 194:1980;599-615.
81. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem. 58:1992;1736-1742.
82. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Striker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.